Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19.

Pubmed ID: 37752063

Pubmed Central ID: PMC10522479

Journal: Influenza and other respiratory viruses

Publication Date: Sept. 1, 2023

MeSH Terms: Humans, Adult, Prospective Studies, Hospitals, Cognition, Depression, COVID-19, Stress Disorders, Post-Traumatic, Delirium

Grants: U01 HL123018, U01 HL123009, UL1 TR002541, UL1 TR001102, U01 HL123004, U01 HL123020, U01 HL123022, U01 HL123031, U01 HL123010, U01 HL123008, U01 HL122989, U01 HL123033, R01 AG058639, UL1 TR002243, U01 HL123023, U01 HL122998, U01 HL123027

Authors: Thompson BT, Hough CL, Gong MN, Lindsell CJ, Semler MW, Rice TW, Brown SM, Collins SP, Jackson JC, Han JH, Orun OM, Casey JD, Clark L, Cordero K, Ginde AA, Iwashyna TJ, Kiehl AL, Lauck A, Leither LM, Patel MB, Raman R, Ringwood NJ, Sheppard KL, Ely EW, Self WH

Cite As: Han JH, Jackson JC, Orun OM, Brown SM, Casey JD, Clark L, Collins SP, Cordero K, Ginde AA, Gong MN, Hough CL, Iwashyna TJ, Kiehl AL, Lauck A, Leither LM, Lindsell CJ, Patel MB, Raman R, Rice TW, Ringwood NJ, Sheppard KL, Semler MW, Thompson BT, Ely EW, Self WH, National Heart Lung and Blood Institute PETAL Clinical Trials Network. Modifiable in-hospital factors for 12-month global cognition, post-traumatic stress disorder symptoms, and depression symptoms in adults hospitalized with COVID-19. Influenza Other Respir Viruses 2023 Sep;17(9):e13197.

Studies:

Prevention and Early Treatment of Acute Lung Injury (PETAL) Network - Outcomes Related to COVID-19 treated with Hydroxychloroquine among In-patients with symptomatic Disease (ORCHID)

Abstract

BACKGROUND: We sought to identify potentially modifiable in-hospital factors associated with global cognition, post-traumatic stress disorder (PTSD) symptoms, and depression symptoms at 12 months. METHODS: This was a multi-center prospective cohort study in adult hospitalized patients with acute COVID-19. The following in-hospital factors were assessed: delirium; frequency of in-person and virtual visits by friends and family; and hydroxychloroquine, corticosteroid, and remdesivir administration. Twelve-month global cognition was characterized by the MOCA-Blind. Twelve-month PTSD and depression were characterized using the PTSD Checklist for the DSM-V and Hospital Anxiety Depression Scale, respectively. FINDINGS: Two hundred three patients completed the 12-month follow-up assessments. Remdesivir use was associated with significantly higher cognition at 12 months based on the MOCA-Blind (adjusted odds ratio [aOR] = 1.98, 95% CI: 1.06, 3.70). Delirium was associated with worsening 12-month PTSD (aOR = 3.44, 95% CI: 1.89, 6.28) and depression (aOR = 2.18, 95% CI: 1.23, 3.84) symptoms. Multiple virtual visits per day during hospitalization was associated with lower 12-month depression symptoms compared to those with less than daily virtual visits (aOR = 0.40, 95% CI: 0.19, 0.85). CONCLUSION: Potentially modifiable factors associated with better long-term outcomes included remdesivir use (associated with better cognitive function), avoidance of delirium (associated with less PTSD and depression symptoms), and increased virtual interactions with friends and family (associated with less depression symptoms).